NO20043834L - Farmasoytisk sammensetning omfattende N-((1-N-butyl-4-piperidinyl)metyl-3,4-dihydro-2H-(1,3)-oksazino(3,2-A)indol-l0-karboksyamid eller salter og fremgangsmate derfor omfattende torr granulering - Google Patents

Farmasoytisk sammensetning omfattende N-((1-N-butyl-4-piperidinyl)metyl-3,4-dihydro-2H-(1,3)-oksazino(3,2-A)indol-l0-karboksyamid eller salter og fremgangsmate derfor omfattende torr granulering

Info

Publication number
NO20043834L
NO20043834L NO20043834A NO20043834A NO20043834L NO 20043834 L NO20043834 L NO 20043834L NO 20043834 A NO20043834 A NO 20043834A NO 20043834 A NO20043834 A NO 20043834A NO 20043834 L NO20043834 L NO 20043834L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
dry granulation
granules
weight
oxazino
Prior art date
Application number
NO20043834A
Other languages
English (en)
Inventor
Philip Christopher Buxton
Sharon Elizabeth Groves
Seona Thomson
Dick Marinus Johannes Va Schie
Kenneth Trevor Yeates
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203528A external-priority patent/GB0203528D0/en
Priority claimed from GB0203526A external-priority patent/GB0203526D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20043834L publication Critical patent/NO20043834L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20043834A 2002-02-14 2004-09-13 Farmasoytisk sammensetning omfattende N-((1-N-butyl-4-piperidinyl)metyl-3,4-dihydro-2H-(1,3)-oksazino(3,2-A)indol-l0-karboksyamid eller salter og fremgangsmate derfor omfattende torr granulering NO20043834L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0203528A GB0203528D0 (en) 2002-02-14 2002-02-14 Process and composition
GB0203526A GB0203526D0 (en) 2002-02-14 2002-02-14 Process and composition
PCT/GB2003/000217 WO2003068193A1 (en) 2002-02-14 2003-01-22 Pharmaceutical composition comprising n- ((1-n-butyl-4-piperidinyl) methyl)-3, 4-dihydro-2h- (1, 3) oxazino (3, 2-a) indole-10-carboxamide or salt and process therefor comprising dry granulation

Publications (1)

Publication Number Publication Date
NO20043834L true NO20043834L (no) 2004-10-26

Family

ID=27736214

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043834A NO20043834L (no) 2002-02-14 2004-09-13 Farmasoytisk sammensetning omfattende N-((1-N-butyl-4-piperidinyl)metyl-3,4-dihydro-2H-(1,3)-oksazino(3,2-A)indol-l0-karboksyamid eller salter og fremgangsmate derfor omfattende torr granulering

Country Status (21)

Country Link
US (1) US20050075335A1 (no)
EP (1) EP1476136B1 (no)
JP (1) JP2005523276A (no)
KR (1) KR100967782B1 (no)
AT (1) ATE329581T1 (no)
AU (1) AU2003202058B2 (no)
BR (1) BR0307666A (no)
CA (1) CA2475659A1 (no)
CO (1) CO5611095A2 (no)
CY (1) CY1106148T1 (no)
DE (1) DE60306120T2 (no)
DK (1) DK1476136T3 (no)
ES (1) ES2263949T3 (no)
IS (1) IS2393B (no)
MX (1) MXPA04007857A (no)
NO (1) NO20043834L (no)
NZ (1) NZ534333A (no)
PL (1) PL206544B1 (no)
PT (1) PT1476136E (no)
RU (1) RU2329789C2 (no)
WO (1) WO2003068193A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
CA2406592C (en) * 2002-10-04 2003-09-30 Duchesnay Inc. Method of preparing pharmaceutical dosage forms containing multiple active ingredients
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
CA2649848A1 (en) * 2006-05-04 2007-11-15 Novartis Ag Heated roller compaction process for making pharmaceutical compositions
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
PL2170292T3 (pl) * 2007-06-22 2014-06-30 Bristol Myers Squibb Holdings Ireland Tabletkowane kompozycje zawierające atazanawir
JP5623275B2 (ja) * 2007-07-31 2014-11-12 カーギル インコーポレイテッド 直接打錠可能なデキストロース
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
TWI461213B (zh) * 2009-11-05 2014-11-21 Fmc Corp 作為藥物賦形劑之微晶纖維素及磷酸鈣之組合物
TW201129386A (en) * 2009-11-05 2011-09-01 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
RU2564922C2 (ru) * 2011-04-19 2015-10-10 Григорий Яковлевич ЛЕГИН Композиция для изготовления спороцидных композиций надуксусной кислоты, способ (варианты) и набор для его осуществления
US9606054B2 (en) 2013-09-30 2017-03-28 Advantest Corporation Methods, sampling device and apparatus for terahertz imaging and spectroscopy of coated beads, particles and/or microparticles
US9417181B2 (en) 2014-05-08 2016-08-16 Advantest Corporation Dynamic measurement of density using terahertz radiation with real-time thickness measurement for process control
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
CN104945303B (zh) * 2015-06-15 2017-09-29 浙江工业大学 3‑烯基吲哚类化合物的制备方法
PE20221838A1 (es) 2020-04-24 2022-11-29 Astrazeneca Ab Formulaciones farmaceuticas
KR102499289B1 (ko) * 2022-04-15 2023-02-14 주식회사 비에스앤코 가루치약의 제조방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3134719A (en) * 1962-04-05 1964-05-26 American Cyanamid Co Calcium phosphates in tablet compressing
US5066441A (en) * 1980-12-12 1991-11-19 Rhone-Poulenc Basic Chemicals Co. Process for compacting a calcium phosphate composition
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
US4713245A (en) * 1984-06-04 1987-12-15 Mitsui Toatsu Chemicals, Incorporated Granule containing physiologically-active substance, method for preparing same and use thereof
EP0376331A3 (en) * 1988-12-29 1991-03-13 Asahi Kogaku Kogyo Kabushiki Kaisha Slow release drug delivery granules and process for production thereof
US5861172A (en) * 1991-05-08 1999-01-19 Laboratorios Beecham Sa Pharmaceutical formulations of compacted granulates of β-lactam antibiotics
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
RU2104279C1 (ru) * 1992-03-12 1998-02-10 Смитклайн Бичам Плс Конденсированное индольное производное или его фармацевтически приемлемая соль, фармацевтическая композиция, проявляющая активность антагониста 5-нт*004-рецептора
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DE4418837A1 (de) * 1994-05-30 1995-12-07 Bayer Ag Thermisches Granulierverfahren
FR2740357B1 (fr) * 1995-10-25 1997-11-28 Rhone Poulenc Chimie Granules redispersables dans l'eau comprenant une matiere active sous forme liquide et un tensio-actif non ionique du type alcoxyles
WO1998007728A1 (en) * 1996-08-16 1998-02-26 Smithkline Beecham Plc PROCESS FOR THE PREPARATION OF N-[(1-nBUTYL-4-PIPERIDYL)METHYL] -3,4-DIHYDRO -2H-[1,3] OXAZINO[3,2-a] INDOLE-10-CARBOXAMIDE AND SALTS AND INTERMEDIATES IN THE PROCESS
MXPA03001210A (es) * 2000-08-07 2004-08-12 Smithkline Beecham Corp Uso de antagonista del receptor 5-ht4 en la fabricacion de un medicamento para la profilaxis o tratamiento de fibrilacion atrial.
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
CA2418921C (en) * 2000-08-08 2010-10-26 Smithkline Beecham P.L.C. Novel composition
US6666298B2 (en) * 2001-11-21 2003-12-23 John Volkman Hanging scaffold support

Also Published As

Publication number Publication date
WO2003068193A1 (en) 2003-08-21
EP1476136B1 (en) 2006-06-14
RU2329789C2 (ru) 2008-07-27
AU2003202058B2 (en) 2009-05-28
US20050075335A1 (en) 2005-04-07
AU2003202058A1 (en) 2003-09-04
HK1072359A1 (en) 2005-08-26
EP1476136A1 (en) 2004-11-17
ATE329581T1 (de) 2006-07-15
KR100967782B1 (ko) 2010-07-05
CO5611095A2 (es) 2006-02-28
DE60306120D1 (de) 2006-07-27
PT1476136E (pt) 2006-10-31
ES2263949T3 (es) 2006-12-16
DK1476136T3 (da) 2006-10-09
NZ534333A (en) 2006-05-26
KR20040097996A (ko) 2004-11-18
DE60306120T2 (de) 2006-11-09
IS7398A (is) 2004-08-12
IS2393B (is) 2008-08-15
JP2005523276A (ja) 2005-08-04
PL371963A1 (en) 2005-07-11
BR0307666A (pt) 2005-01-11
CY1106148T1 (el) 2011-06-08
RU2004127450A (ru) 2005-04-10
PL206544B1 (pl) 2010-08-31
MXPA04007857A (es) 2004-10-15
CA2475659A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
DK1476136T3 (da) Farmaceutisk præparat, der omfatter N-[(1-N-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indol-10-carboxamid eller salt, og fremgangsmåde derfor, der omfatter törgranulering
MX2007007458A (es) Derivados de quinazolina para inhibir crecimiento de celulas cancerigenas y metodo para la preparacion de los mismos.
MXPA02003203A (es) Composiciones terapeuticas solubles en tocol.
CA2470668A1 (en) 5ht4 partial agonist pharmaceutical compositions
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
AU1531199A (en) Pharmaceutical suspension tablet compositions
YU49069B (sh) Postupak za pravljenje formulacije tablete
EP2275121A3 (en) Protein-based streptococcus pneumoniae vaccines
HRP20100399T1 (hr) Oralno dezintegrirajući pripravak olanzapina ili donepezila
RU2008106220A (ru) Гастроретентивные композиции и способ их изготовления
WO2003057150A3 (en) A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
CA2342634A1 (en) Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative
CA2353693A1 (en) Pharmaceutical composition containing citalopram
PT1635792E (pt) Composições farmacêuticas estáveis de derivados do ácido 2-aza-biciclo[3.3.0]octano-3-carboxílico
EA200600675A1 (ru) Гранулы, содержащие гидрохлорид венлафаксина
NO20060208L (no) Farmasoytisk preparat
WO1998018466A3 (en) Anti-neurogenic inflammatory compounds and compositions and methods of use thereof
NO20055536L (no) Fremgangsmate for forbedret diurese i individer med svekket nyrefunksjon
NO20051463L (no) Inhaleringssammensetninger med hoy legemiddelandel
RU2013127273A (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, АДАПТИРОВАННАЯ ДЛЯ ОРАЛЬНОГО ВВЕДЕНИЯ, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ ДЛЯ ПРЕДОТВРАЩЕНИЯ И ЛЕЧЕНИЯ СИНДРОМА РАЗДРАЖЕННОГО КИШЕЧНИКА НА ОСНОВЕ МОДИФИКАТОРА МОТОРИКИ КИШЕЧНИКА И ФЕРМЕНТА α-D-ГАЛАКТОЗИДАЗЫ
PT1461017E (pt) Composicao farmaceutica para a libertacao controlada de um antibiotico beta-lactamico
IL200447A0 (en) Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
UA94275C2 (ru) Фармацевтическая композиция, которая содержит по крайней мере один активный наркотический или психотропный компонент, назначенный способ введения которых в организм тяжело поддается изменению
CA2217238A1 (en) Cross-linked cellulose as a tablet excipient

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application